ag视讯真人体育真人

Australia Biotech Invest 2013
28-29 October 2013
Melbourne Convention and Exhibition Centre,Victoria ,Australia

Benefit from expert analysis on the evolving landscape of biotech investment from:

Join Australia Biotech Invest 2013 to:

• Get up-to date on the latest trends and opportunities in global biotech investment
• Hear 30+ public and private biotech companies present their pipeline and investment case
• Discuss partnering, investment and capital raising strategies with our expert panels
• Gain insight into IP protection issues and find out how best to safeguard your IP rights
• Learn about Australia’s biotech R&D tax incentives and how to benefit from them
• Identify exciting new business opportunities at the on-site exhibition
• Network with biotech CEOs, international investors, big pharma, brokers and industry analysts
• Access our online partnering system to set up 1-to-1 meetings and make more deals!

Australia’s premier biotech investment event
To be held in Melbourne, one of the great 黄金城游戏 hubs in the world, Australia Biotech Invest will be Australia’s biggest biotech investment event to date. Building on AusBiotech’s successful Australasian Life Science Investment Summits, Australia Biotech Invest extends to a two-day programme and will gather together hundreds of 黄金城游戏 investors from Australia and across the globe to discuss investment and partnership opportunities with a line-up of cutting-edge biotech companies.

Combining high-value content with concrete investment opportunities
In addition to biotech company presentations, the programme of Australia Biotech Invest 2013 features a mix of expert keynotes, investor and analyst panels and focus sessions to provide you with valuable market intelligence and act as your guide to biotech investment.

Strong performance for the biotech sector
This year is shaping up to be a good year for investment in the biotech sector. Globally, biotech stocks are surging, in the United States IPOs are being launched at the highest rate in more than 10 years and overall strong performance of the sector has placed biotech back in the investor limelight. With a positive long-term outlook, now is an excellent time to learn more about how to gain exposure to this exciting sector.

Sponsorship and Exhibiting Opportunities:

Who Should Attend?

Biotech companies come and present your pipeline to the assembled audience of investors and big pharma representatives and raise funds or set up partnerships to drive your research forward. Benefits for presenting biotech companies: Gain access to senior professionals representing investable capital globally Pitch your investment case in an 8-minute spotlight presentation on the main 黄金城游戏 stage to the assembled audience Enjoy exposure on the targeted marketing campaign reaching out to our extensive investor database and to key business development professionals in pharma and big biotech Explain further details of your research at your dedicated table top space at the exhibition Set up one-to-one meetings to discuss deals in private Meet with all the key stakeholders under one roof and enjoy excellent networking opportunities throughout the 黄金城游戏

Institutional investors Private equity investors Venture capitalists Angel investors Family offices Fund managers Major pharmaceutical companies Investment banks Brokerage firms Stock exchanges Consultants Analysts Law firms CMOs and CROs Plus: Biotech companies looking for funding or partners

Biotech companies confirmed to present so far include:

For enquiries, please contact:
Australia / New Zealand Speaking & Sponsorship enquiries Hayley Laing T: +613 9828 1400 E:[email protected]	Asia / Rest of the World Speaking enquiries Lot de Jongh T: +852 2531 6140 E:lot.jongh@beacon黄金城游戏.com	Asia / Rest of the World Sponsorship enquiries King Tai T: +852 2531 6125 E:king.tai@beacon黄金城游戏.com

Conference Day One 28 October 2013

08:30	Registration and morning coffee
09:00	WELCOME & OFFICIAL OPENING The Honourable Gordon Rich-Phillips MLC, Minister for Technology, STATE GOVERNMENT OF VICTORIA Glenn Cross, Chief Operating Officer, AUSBIOTECH
09:10	Conference chairman’s opening remarks and business card exchange David Blake, Editor, BIOSHARES
GLOBAL STATE OF BIOTECH INVESTMENT
09:15	Global biotech investment trends and opportunities • Analysing investment and business trends driving biotechnology today • Demographic,macro-economic and policy development simpacting the sector • Exploring innovative investment strategies to benefit from emerging opportunities inbiotech Dr Eric Shiozaki,Director,APPOSITE
09:35	Exploring biotech’s evolving investment landscape – challenges and opportunities Long-term investment outlook for biotech from the investors’ perspective What’s hot in 黄金城游戏s and where is the smart money being invested? Ways to gain exposure to the biotech boom: Stocks, funds, private equity, venture capital or else? Expert investor’ views on the best vehicles for biotech investment Funding the future of biotech: Key challenges and opportunities Moderator: David Blake, Editor, BIOSHARES Panellists: Dr Jonathan Wang, Senior Managing Director, ORBIMED ASIA Jeremy Curnock Cook, Managing Director, BIOSCIENCE MANAGERS Scott Power, Director of Research, RBS MORGANS Dr Joshua Funder, Partner, GBS VENTURE PARTNERS
10:15	Biotech Company Spotlight Presentations Julie Phillips, CEO, BIODIEM (ASX:BDM) Dr John Holaday, Managing Director, CEO and CSO, QRXPHARMA (ASX:QRX) Dr Brad Walsh, CEO, MINOMIC INTERNATIONAL Dr Greg Collier, CEO, INVION (ASX:IVX) Howard Digby, Executive Director, ECOQUEST (ASX:ECQ)
11:00	Morning refreshments and networking with exhibitors
11:30	The changing face of biotech investment Assessing the current state of venture capital and private equity investment into biotech Examining the role of institutional investors in the biotech space Attracting super funds to invest in biotech Managing risk at all stages: Exploring risk mitigation strategies for biotech investors Lessons learned from investing in biotech Moderator: David Blake, Editor, BIOSHARES Panellists: Lawrence Gozlan, Chief Investment Officer and Founder, SCIENTIA CAPITAL Michael Glenane, Executive Director, FAIRVIEW EQUITY PARTNERS John Granger, Founder, HAWKESBURY PARTNERS Graeme Colley, Director of Technical and Professional Standards, SELF MANAGED SUPER FUNDS PROFESSIONALS’ ASSOCIATION OF AUSTRALIA Ron Laufer, Senior Managing Director, MEDIMMUNE VENTURES
12:15	Biotech Company Spotlight Presentations Dr Deborah Rathjen, CEO, BIONOMICS (ASX:BNO) Dr Paul MacLeman, Chief Executive Officer, IDT AUSTRALIA (ASX:IDT) Dr Malcolm McColl, CEO, VIRALYTICS (ASX:VLA) Dr Michelle Miller, CEO, BIOTRON (ASX:BIT) Charles Walker, Chief Executive Officer, ALCHEMIA (ASX:ACL)
13:00	Lunch and networking with exhibitors
VALUATION & RISK ASSESSMENT
14:00	Valuing biotech opportunities and optimising risk-return ratios • Identifying investment opportunities and risk-return prospects across the development and patent lifecycle of a biotech company • Putting a 黄金城游戏 on biotech:How to value patents,management track records and expected future revenue/royalty streams • Ten key factors to keep in mind when investing into 黄金城游戏 companies • Small,mid or large-cap?De-risking your portfolio by diversifying your biotech holding • Utilising the discovery investment scoreboard technology to pick the best stocks Dr Michael A• Berry,ManagingDirector,DISCOVERY INVESTING
PARTNERING STRATEGIES
14:20	PHARMA PANEL: Strategic partnering for long-term success Examining successful partnership models: How to achieve a win-win partnership Commercialising innovation: Impact of strategic alliances and JVs on cost / revenue models and success rate of drug development Partnerships key challenges and opportunities Moderator: David Blake, Editor, BIOSHARES Panellists: Augustine Yee, Asia Pacific Head of Regional and Corporate Business Development and China Vice President of Business Development,ASTRAZENECA Dr James Garner, Vice President & General Manager, Takeda Global Research & Development Centre Asia, TAKEDA Dr Martin Judge, Director, Strategy and Sourcing, NOVO NORDISK A/S Dr Brian Bloomquist, Senior Director, Global External Research and Development, ELI LILLY Dr Raman Rao, Head External R&D, Asia Pacific, SANOFI PASTEUR
15:00	Biotech Company Spotlight Presentations Carl Stubbing, Chief Business Officer, BENITEC BIOPHARMA (ASX:BLT) Dr Julian Chick, COO, ALLIED HEALTHCARE GROUP (ASX:AHG) Dr Andrea Grant, CEO, LIVING CELL TECHNOLOGIES (ASX:LCT) Mark Diamond, Managing Director & CEO, ANTISENSE THERAPEUTICS (ASX:ANP)
15:35	Afternoon tea and networking with exhibitors
R&D and TAX INCENTIVES
16:00	Maximising your after tax return on investment in Australia – strategies and opportunities Tax and financial structures for start-ups in order to leverage the R&D incentive and maximise Return on Investment Current “state of play” of the R&D tax incentives and grants available Biotech start-up tax case study – tips and traps for first time and experienced applicants, including tax and R&D considerations Australian Manufacturing Incentive Helen Fisher, Corporate & International Tax Partner, DELOITTE Sergio Duchini, R&D & Government Incentives Partner, DELOITTE
ANALYSTS’ VIEW
16:45	ANALYST ROUNDTABLE: Analysing the biotech boom Biotech drivers and performance in Australia and New Zealand What stocks are on the analysts’ watchlist and why? Moderator: David Blake, Editor, BIOSHARES Panellists: Marc Sinatra, Equities Analyst, LODGE PARTNERS Dr Graeme Wald, Investment Director, BIOSCIENCE MANAGERS Scott Power, Director of Research, RBS MORGANS Dr Matthijs Smith, Senior Analyst, CANACCORD GENUITY
17:30	Networking Drinks Reception

Conference Day Two 29 October 2013

08:30	Registration and morning coffee
09:00	Conference chairman’s opening remarks and day one recap
	Dr Fintan Walton, Founder and CEO, PHARMAVENTURES
BIOTECH PERFORMANCE AND GROWTH OUTLOOK
09:15	Biotech financing and business models for future growth • Key success factors and business models to monetise innovation • Access to finance:Capital raising for early and late-stage biotechs • Investment exit strategies anno 2013 Kellee Kim,ResearchAnalyst,ECOR1CAP
09:35	BIOTECH BROKERS PANEL: Outlook for 黄金城游戏 stocks Assessing the performance of 黄金城游戏 stocks across key exchanges Spotlight on recent listings and upcoming IPOs Small-cap, mid-cap, large-cap: Where are the best opportunities? Moderator: Dr Fintan Walton, Founder and CEO, PHARMAVENTURES Panellists: Joanna Hill, Client Services Manager, EL & C BAILLIEU STOCKBROKING Steven Yatomi-Clarke, Director Corporate Finance, PATERSONS SECURITIES Sam Street, Associate Director Corporate Finance, RBS MORGANS James Posnett, Manager, Listing Business Development, ASX
10:15	Biotech Company Spotlight Presentations Geoffrey Kempler, Executive Chairman, PRANA BIOTECHNOLOGY (ASX:PBT) Dr Tom McCarthy, Chief Executive Officer & Managing Director, SPINIFEX PHARMACEUTICALS Roger McPherson, CFO, PATRYS (ASX:PAB) Dr Geoff Cumming, CEO, ANTEO DIAGNOSTICS (ASX:ADO) Dr Cliff Holloway, CEO, IMMUNE SYSTEM THERAPEUTICS
11:00	Morning refreshments and networking with exhibitors
11:30	Spotlight on Victoria’s biotechnology industry capabilities Representative, VICTORIAN GOVERNMENT
PROTECTING YOUR IP RIGHTS
12:00	IP Due Diligence for capital raising and investment Potential threats to a biotech company’s IP rights Getting your IP house in order prior to raising capital Security around IP that investors should seek when investing into biotech
12:30	Biotech Company Spotlight Presentations Simon Wilkinson, Director & CEO, INNATE IMMUNOTHERAPEUTICS Nick Weston, Chairman & CEO, AGENIX (ASX: AGX) Mike Thomas, CEO, ISONEA (ASX:ISN) Marc Storms, Marketing Manager, FEI (NASDAQ:FEIC)
13:05	Lunch and networking with exhibitors
ASIA AND CHINA FOCUS SESSION
14:15	Asia’s growing role in biotech innovation and investment • Examining Asia’s biotech landscape and key drivers for future growth • Flows of biotech innovation and investment into and out of Asia • Market outlook and opportunities for Australian-Asian partnerships Dr Jason Mann,ManagingDirector,FENEX CAPITAL MANAGEMENT
14:35	How to access investment out of China? What do investors in China look for when investing into biotech companies? What types of companies at what stage are most favoured? Pitch perfect: How can biotech companies best position themselves to attract capital and/or set up partnerships in China? Exploring biotech capital raising success stories and successful investor exits Accessing grants and funding and collaborating across borders Moderator: Dr Fintan Walton, Founder and CEO, PHARMAVENTURES Panellists: Rob Scott, Director, CHINA BLUESKY VENTURES Dr Benjamin Chen, Managing Partner, IGNATIUS TRANSACTION PARTNERS David Cheng, Chief Investment Officer, COLAND HOLDINGS Dr Jason Mann, Managing Director, FENEX CAPITAL MANAGEMENT
15:05	Biotech Company Spotlight Presentations Uwe Schlokat, CEO, SENTINEXT THERAPEUTICS Mark Heffernan, Chief Executive Officer, NEXVET BIOPHARMA Nick Ede, Executive Director, IMUGENE (ASX:IMU) Dr Clement Leong, Chief Executive Officer,ASCEND BIOPHARMACEUTICALS
15:40	Afternoon tea and networking with exhibitors
THE FUTURE OF BIOTECH INVESTMENT
16:00	Creating value from spin-offs
	Role of universities to drive the next generation of biotech innovation Importance of university spin-offs to put research to commercial use How to create investor value from spin-offs: Success stories and lessons learned Moderator: Dr Fintan Walton, Founder and CEO, PHARMAVENTURES Panellists: Dr Chris Nave, Chief Executive Officer, MEDICAL RESEARCH COMMERCIALISATION FUND Dr John Kurek, Investment Manager, UNISEED VENTURES Dr Mel Billingsley, President and CEO, THE LIFE SCIENCES GREENHOUSE OF CENTRAL PENNSYLVANIA Ron Laufer, Senior Managing Director, MEDIMMUNE VENTURES
16:30	Biotech Company Spotlight Presentations Dr Richard Hopkins, CEO, PHYLOGICA (ASX: PYC) Paul Wright, Chief Executive Officer, UNIVERSAL BIOSENSORS (ASX:UBI)
16:50	Key challenges and investment opportunities for biotech in coming 10 years
	Key challenges and opportunities for biotech investment and innovation going forward Who will be funding early stage biotech to keep the momentum going? Key trends in the healthcare space and how these may affect biotech innovation and investment in the years to come Will biotech live up to its potential? Moderator: Dr Fintan Walton, Founder and CEO, PHARMAVENTURES Panellists: Glenn Cross, Chief Operating Officer, AUSBIOTECH Todd Davis, Managing Director, HEALTHCARE ROYALTY PARTNERS Eric Shiozaki, Director, APPOSITE CAPITAL Rhenu Bhuller, Global Vice President Pharmaceuticals/Biotechnology, FROST & SULLIVAN Dr Stewart Washer, Chairman, ISONEA
17:30	Chairman’s closing remarks and end of 黄金城游戏

Profiles of previous delegates to Asia Biotech Invest 2013:

COMPANY TYPE	Investors attending Asia Biotech Invest 2013 included: 8T8 Capital • AK Partners HK • AP Capital Group • Asia Pacific Investment Advisors • Avenue Capital Group • Ballingal Investment Advisors • Baring Private Equity Partners Asia • Baron Group Baron Capital • Bioscience Managers • BioVeda China Fund • BOCI-Prudential Asset Management • Business Succession Partners • Caitong International Asset Management • Capvest & Associates • CCB International Asset Management • Cedrus Investments HK • Celadon Capital Malaysia • Chepstow Capital Advisors • China BlueSky Ventures • CMS Asset Management HK • Creata Group • DAC Financial Management China • Decheng Capital • Deltec Capital • Discovery Investing • Ellis Brady Management HK • Etoile Asset Management • Fortune Time Capital Holding Group • Franklin Templeton Investments Asia • Global Mining Capital Corporation • Gottex Penjing Asset Management • Green Mountains Investments • Greenwoods Asset Management • Guangdong International Capital • GYK Holdings • Harmony Asset Management • Hong Kong Institute of Biotechnology • Infinity Group • JAG Investments • JPMorgan Asset Management Real Assets Asia • Kaiwu Capital • Khazanah Nasional Berhad • Leon CVM Capital Management Hong Kong • LGT Capital Partners Asia Pacific • Lilly Asia Ventures • Lim Global Investment & Research • Liomer Holdings • M H Carnegie & Co • Muse Capital • Nan Fung Group • Optivest Capital • OrbiMed Asia • Pacific West Asia Asset Management • PharmaVentures • Primavera Capital • Qiming Ventures • Quadria Capital • Qualita • Quam • RimAsia Capital Partners • Rock Spring Ventures • RRJ Management HK • Saba Capital • Sequoia Capital • Shaw Kwei & Partners • Sinovest Capital • STIC Investment • Stratagem Capital • Sumitomo Mitsui Asset Management HK • The Bank of East Asia • The Longreach Group • Tian An China Investments • Tripod Capital • Valiant Ocean Investment • Ventac Partners HK • Vivo Ventures • Wellcome Trust • Yuuwa Capital
JOB FUNCTION
INVESTORS - JOB FUNCTION

“From its first edition, Asia Biotech Invest is already the ‘must-go’ event for both biotech investors and fund-seekers in Asia” Andrew Badrot, CMS Advisors

“As the world becomes increasingly Asia-centric, it is essential that our company develops links and contacts in the Biotech and Investment communities in Asia. The work of AusBiotech in proactively assisting in this through the Asia Biotech Invest summit enabled us to link in effectively and quickly. We’ll be back.” Sean Parsons, Ellume

“We were very pleasantly surprised by the number and calibre of the investors that attended the meeting. We had a number of very productive meetings and are pursuing two strong leads in our capital raising efforts directly as a result of the Asia Biotech Invest meeting.” Dr Brad Walsh, Minomic International

---

Media Partners

To register, visit:
call +852 2219 0111, email info@beacon黄金城游戏.com, or fax to +852 2219 0112